Nasdaq:BOLT
Bolt Biotherapeutics, Inc.
A clinical-stage biotech firm developing next-generation immune cell therapies for blood cancers using its proprietary Bolt Cell Therapy Platform.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock for exposure to the high-growth cell therapy sector with potential transformative treatments for blood cancers. The company holds a robust balance sheet relative to its size with $57.2M in shareholders equity and $40.1M in marketable securities to fund development milestones. Successful product launches could bridge the gap between current losses and future profitability.
Bear Case
The stock carries substantial risk due to persistent net losses of -$63.1M and a retained earnings deficit of -$427.4M indicating limited financial buffer. Revenue growth has stagnated at $7.7M in 2024 compared to $7.9M in 2023, suggesting challenges in scaling commercial operations or product uptake. High R&D spending of $57.5M without current revenue diversification creates significant pressure on cash reserves.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biotechnology company focused on developing novel therapies for hematologic malignancies using its proprietary Bolt Cell Therapy Platform. The company serves the oncology market with products designed to enhance immune cell function to target cancer cells, specifically leveraging CAR T-cell and NK cell technologies. Recent financials show a revenue trend of approximately $7.7M in 2024 alongside significant R&D investments totaling $57.5M.
Analysis
Management Discussion
Management has maintained a disciplined approach with operating expenses at $80.7M while generating gross profit of $7.7M, though the company continues to report a net loss of -$63.1M. Cash position decreased by $3.6M year-over-year from $12.6M beginning cash to $9.0M ending cash, reflecting heavy investment in R&D and working capital changes of -$12.2M.
Industry Overview
The cell and gene therapy industry is characterized by high capital intensity and long development cycles but offers the potential for blockbuster oncology treatments. Companies like Bolt Biotherapeutics compete with established pharmaceutical giants and other biotech firms developing similar immunotherapy approaches for hematologic malignancies. Regulatory pathways remain rigorous, requiring extensive clinical data to demonstrate safety and efficacy before market entry.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $5.7M | $7.9M | $7.7M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $5.7M | $7.9M | $7.7M |
| Operating Expenses | $96.0M | $84.1M | $80.7M |
| Operating Income | $-90.3M | $-76.2M | $-73.0M |
| R&D | $73.1M | $61.5M | $57.5M |
| G&A | $22.9M | $22.5M | $18.5M |
| Stock-Based Comp | $9.6M | $9.2M | $7.4M |
| D&A | $1.7M | $1.9M | $1.8M |
| Depreciation | $1.7M | $1.9M | $1.8M |
| Other OpEx | $0 | $0 | $4.8M |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-90.3M | $-76.2M | $-73.0M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-90.3M | $-76.2M | $-73.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-88.1M | $-69.2M | $-63.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-88.1M | $-69.2M | $-63.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $172.7M | $105.7M | $50.8M |
| Cash & Equivalents | $9.2M | $10.8M | $7.2M |
| Marketable Securities | $159.6M | $91.4M | $40.1M |
| Prepaid Expenses | $3.9M | $3.5M | $2.7M |
| Other Current Assets | $0 | $0 | $784.0K |
| Long-Term Assets | $55.1M | $54.1M | $48.8M |
| PP&E (Net) | $6.5M | $5.0M | $3.1M |
| Operating Leases | $22.1M | $19.1M | $21.8M |
| LT Investments | $23.9M | $26.4M | $22.9M |
| Other LT Assets | $2.6M | $3.6M | $1.0M |
| Total Assets | $227.8M | $159.8M | $99.6M |
| Current Liabilities | $23.1M | $20.5M | $15.9M |
| Accounts Payable | $3.6M | $3.0M | $1.5M |
| Current Leases | $2.4M | $2.8M | $2.3M |
| Deferred Revenue | $1.4M | — | — |
| Other Current Liab | $15.7M | $14.7M | $12.1M |
| Long-Term Liabilities | $33.2M | $26.6M | $26.6M |
| LT Operating Leases | $20.2M | $17.4M | $23.0M |
| Other LT Liab | $13.0M | $9.2M | $3.6M |
| Total Liabilities | $56.3M | $47.0M | $42.4M |
| Shareholders' Equity | $171.5M | $112.7M | $57.2M |
| Retained Earnings | $-295.1M | $-364.3M | $-427.4M |
| AOCI | $-919.0K | $37.0K | $97.0K |
| Total L&E | $227.8M | $159.8M | $99.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-88.1M | $-69.2M | $-63.1M |
| Non-Cash Adjustments | $10.2M | $6.2M | $14.0M |
| Working Capital Changes | $1.3M | $-6.6M | $-12.2M |
| Cash from Operations | $-76.5M | $-69.5M | $-61.3M |
| Capital Expenditures | $2.0M | $206.0K | $41.0K |
| Cash from Investing | $57.9M | $71.0M | $57.6M |
| Cash from Financing | $503.0K | $253.0K | $108.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-18.1M | $1.8M | $-3.6M |
| Beginning Cash | $28.9M | $10.8M | $12.6M |
| Ending Cash | $10.8M | $12.6M | $9.0M |
Frequently Asked Questions
How does Bolt Biotherapeutics, Inc. make money?
The company's primary revenue stream is derived from product sales or licensing related to its hematologic malignancy treatments, supported by a substantial research and development budget of $57.5M focused on advancing its CAR T-cell and NK cell technologies.
What are the main risks for BOLT?
1. Clinical trial failure risks inherent to clinical-stage biotechnology development. 2. Significant operating losses of -$63.1M impacting burn rate and capitalization needs. 3. Dependence on successful regulatory approval for product commercialization. 4. Dilution risk from cash flow financing activities of $108,000 indicating potential equity issuance.
What is BOLT's competitive advantage?
1. Proprietary Bolt Cell Therapy Platform enabling differentiated immune cell products. 2. Strong focus on hematologic malignancies with potential for high-value oncology treatments. 3. Strategic cash flow management evidenced by $40.1M in marketable securities providing liquidity runway.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.